An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Vorinostat (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms VANTAGE-095
- Sponsors Merck Sharp & Dohme
- 18 Apr 2012 Actual end date changed from Mar 2012 to Apr 2012 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Actual patients number is 143 as reported by ClinicalTrials.gov.
- 13 Apr 2012 Actual end date changed from 1 May 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.